Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05262400 · ClinicalTrials.gov registry record · Phase 1
A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors
A Phase 1 study of Breast Cancer and Solid Tumors, sponsored by Pfizer.
- Active
- Registry status
- Phase 1
- Development phase
- 192
- Enrollment target
- 20
- Study locations
NCT05262400: Active Phase 1 study of Breast Cancer and Solid Tumors, sponsored by Pfizer.
NCT05262400 is a Phase 1 study of Breast Cancer and Solid Tumors that is active but no longer recruiting, run by Pfizer. The registered enrollment target is 192 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (93% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05262400, a Phase 1 study of Breast Cancer and Solid Tumors, is active but no longer recruiting, sponsored by Pfizer.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 192 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07220060 and PF-07104091) in people with breast cancer. This clinical study consists of 2 parts (part 1 and part 2). In part 1, we are seeking participants who: * Have been diagnosed with Breast Cancer (BC) of either types: * Have HR+, HER2- BC * Refractory HR-positive/HER2-positive BC * Have other solid tumors other than BC In part 2, we are seeking participants who: -Have HR-positive/HER2-negative BC Part 1 will include increasing doses of PF-07220060 with PF-07104091. In part 2, participants will take 1 of 2 study medicine combinations. This will help us decide the highest amount of study medicines that can be safety given to people. All participants in this study will receive PF-07220060 with PF-07104091 by mouth. We will compare participant experiences to help us determine if PF-07220060 with PF-07104091 is safe and effective. Participants will take part in this study for about 2 years. During this time, they will receive the study medicine, an x-ray imaging, and will be observed for safety and effects of the study medicines.
Primary Outcome
Number of participants with DLTs, which are typically Grade 3 or higher adverse events will be summarized by dose level
Conditions Studied
Interventions
- DRUG PF-07220060 + PF-07104091 combination dose escalation
Study Locations (20)
California
- Administrative Address: UCLA Hematology/Oncology - Los Angeles
- Ronald Reagan UCLA Medical Center - Los Angeles
- UCLA Hematology/Oncology - Los Angeles
- UCLA Hematology / Oncology-Parkside - Santa Monica
- UCLA Hematology/Oncology-Santa Monica - Santa Monica
Other
- Centro Oncologico Korben - Buenos Aires
- Clínica Universitaria Reina Fabiola - Córdoba
- Fundación CORI para la Investigación y Prevención del Cáncer - La Rioja
Rio Grande do Sul
- ONCOSITE - Centro de Pesquisa Clinica em Oncologia - Ijuí
- Centro Gaucho Integrado De Oncologia, Hematologia, Ensino E Pesquisa - Porto Alegre
- Centro de Pesquisa Clínica - Área Administrativa - Porto Alegre
Texas
- Texas Oncology-Baylor Charles A. Sammons Cancer Center - Dallas
- The University of Texas MD Anderson Cancer Center - Houston
Washington
- Swedish Medical Center - Seattle
- Swedish Medical Center - Seattle
Massachusetts
- Massachusetts General Hospital - Boston
Michigan
- START Midwest - Grand Rapids
Missouri
- Saint Luke's Cancer Institute - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 192 participants |
| Start Date | 2022-03-14 |
| Est. Completion | 2026-08-23 |
| Phase | Phase 1 |
What the registry record for NCT05262400 still lists
NCT05262400 is an interventional study that assigns participants to a tested intervention. The registered 192 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (93% lower).
The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which PF-07220060 + PF-07104091 combination dose escalation is the first listed.
NCT05262400 names 20 study sites across 10 states, led by California, Other, Rio Grande do Sul.
Frequently Asked Questions
What is clinical trial NCT05262400 about?
NCT05262400 is a clinical study titled "A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors". The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07220060 and PF-07104091) in people with breast cancer. This clinical study consists of 2 parts (part 1 and part 2). In part 1, we are seeking participants who: * Have been diagnosed with Br...
What is the current status of trial NCT05262400?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 192 participants. The study started on 2022-03-14. Estimated completion is 2026-08-23.
What conditions does trial NCT05262400 study?
This clinical trial studies the following conditions: Breast Cancer, Solid Tumors.
What interventions are being tested in trial NCT05262400?
The interventions under investigation include: PF-07220060 + PF-07104091 combination dose escalation (DRUG).
Who is sponsoring clinical trial NCT05262400?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05262400 being conducted?
This trial has 20 study locations across California, Massachusetts, Michigan, Missouri, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05262400's enrollment target sits among peer trials
192 390th of 1224 higher than 835 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01492972 · 192 participants · Phase 3
Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
- NCT01973881 · 192 participants
Quantitative MRI for Myelofibrosis
- NCT02535702 · 192 participants · NA
Development Of Neuroimaging Methods To Assess The Neurobiology Of Addiction
- NCT03622359 · 192 participants · NA
Radiotracer-Based Perfusion Imaging of Patients With Peripheral Arterial Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI